Together in 2015, we raised $2.65 million for cancer research at Fred Hutch. This research spans everything from lifestyle choices to environmental and genetic factors that contribute to cancer risk. The complete picture helps inform understanding of what’s needed to cure cancer.
In the coming weeks, we’ll share information on the types of research Obliteride helps fund. We’ll do our best to introduce you to the work, pique your interest and connect you with more detail. Here is the first in the series of blogs that will introduce the types of work you’re making possible.
CLINICAL RESEARCH SUPPORT (CRS)
As an NCI-designated Comprehensive Cancer Research Center, Fred Hutch and its research collaborators, the University of Washington, Seattle Children’s, and the Seattle Cancer Care Alliance, form the Fred Hutchinson/University of Washington Cancer Consortium and stands among the most distinguished places for cancer research and care in the United States. This distinction means we’re eligible for the vital NCI research funds that have powered so many discoveries at Fred Hutch for the past 40 years and will continue to do so. These discoveries hinge on our ability to push the edge of science and that’s where Clinical Research Support (CRS) comes in.
Clinical trials are the way we make advances in how we detect, diagnose and treat cancer. It’s where ideas and innovation become cures for patients. These trials happen collaboratively across the Cancer Consortium and CRS is here to assure preeminent science makes its way to our patients in the safest manner.
CRS serves as the central resource of clinical research experts that work with and support faculty and study teams across the Cancer Consortium allowing them to do their best work fastest.
It’s because of their work that we conducted over 600 clinical trials last year and treated nearly 1,000 patients on those trials. While supporting and monitoring trials across the Cancer Consortium, their office also does things like fast-track requests from the FDA for things like “Expanded Access”, whereby patients with little hope—even with only a few days left—might gain access to a promising, yet not fully-proven treatment. This is where we learn and in the best cases, save lives immediately.
In 2015, funds from our riders on the teams at Seattle Children’s, UWMC and the SCCA went to support CRS. It’s a powerful symbol of how we all work together to advance our shared knowledge. Thank you.
Click here to learn more about Clinical Research Support at Fred Hutch.